-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Chemed, Raises Price Target to $674

Benzinga·04/28/2025 16:01:15
Listen to the news
RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $667 to $674.